1. Volume 14, Issue 7, Pages 627-637 (June 2013)
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial 
Thomas Crosby, FRCR, Christopher N Hurt, MSc, Stephen Falk, MD, Simon Gollins, FRCR, Somnath Mukherjee, FRCP, John Staffurth, MD, Ruby Ray, PhD, Nadim Bashir, BSc, John A Bridgewater, FRCP, J Ian Geh, FRCP, Prof David Cunningham, FRCP, Prof Jane Blazeby, MD, Rajarshi Roy, FRCR, Prof Tim Maughan, FRCP, Gareth Griffiths, MSc 
The Lancet Oncology 
Volume 14, Issue 7, Pages (June 2013)
DOI: /S (13)
Copyright © 2013 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

3. Figure 2 Kaplan-Meier curves of overall survival by treatment group
CRT=chemoradiotherapy.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

4. Figure 3
Hazard ratio plots for overall survival, by baseline characteristics
Survival data are median number of months (95% CI) in all patients. Positions of squares show hazard ratio of death in the CRT plus cetuximab group compared with death in the CRT only group; the area of each square represents the amount of information (ie, the number of patients) in each category. Lines show 95% CIs. CRT=chemoradiotherapy. NC=not calculable because of small numbers of patients.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

5. Figure 4
Physical functioning score from QLQ-C30 in each treatment group at five timepoints over 52 weeks
The number of patients shows the amount who completed QLQ-C30 at each timepoint. A higher score indicates better function. Bars show 95% CI. QLQ-C30=European Organisation for Research and Treatment of Cancer's Quality of Life Questionnaire C30.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

6. Figure 5
Eating restrictions score from QLQ-OES18 in each treatment group at five timepoints over 52 weeks
The number of patients shows the amount who completed QLQ-OES18 at each timepoint. A higher score indicates a greater number of problems. Bars show 95% CI. QLQ-OES18=European Organisation for Research and Treatment of Cancer's Quality of Life Questionnaire OES18.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions